# Targretin Capsulesgel

**cutaneous T-cell lymphoma**

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Retinoid X Receptor Activator</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Targretin (bexarotene)</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code(s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>TARGRETIN</td>
<td>045771</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TARGRETIN</td>
<td>044269</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong> </th>
<th><strong>Question ID</strong> </th>
<th><strong>Default Next Question ID</strong> </th>
<th><strong>Question Type</strong> </th>
<th><strong>Question Text</strong> </th>
<th><strong>Choice Text</strong> </th>
<th><strong>Next Question ID</strong> </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>1000</td>
<td></td>
<td>Select</td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? </td>
<td>Y</td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>2</td>
<td>1001</td>
<td> </td>
<td>Select </td>
<td>Is the medication being prescribed by an oncologist?</td>
<td>Y</td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>3</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td>Which medication is being requested?</td>
<td>Targretin (bexarotene) Capsules</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Targretin (bexarotene) Gel</td>
<td>2000</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="even">
<td>4</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response to at least one prior systemic therapy?</p>
<p>If yes, please provide documentation. </p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>5</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of the patient’s baseline complete blood count (CBC), fasting lipid profile, liver function tests, and thyroid profile prior to initiation of therapy?</p>
<p>If yes, please provide documentation.</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>6</td>
<td>2000</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response to at least 3 of the following:</p>
<ol type="1">
<li><p>Local radiation</p></li>
<li><p>Phototherapy</p></li>
<li><p>Topical carmustine</p></li>
<li><p>Topical corticosteroids</p></li>
<li><p>Topical imiquimod</p></li>
<li><p>Topical mechlorethamine (mustard)</p></li>
</ol>
<p>If yes, please provide documentation. </p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>7</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days

| **Last Approved** | 4/10/2023 |
| ----------------- | --------- |
| **Other**         |           |
